Ascelia Pharma (ACE) Q4 2025 earnings summary

Executive summary

• FDA accepted the NDA for Orviglance, a first-in-class liver MRI contrast agent for cancer patients with severe kidney impairment, with a PDUFA date set for July 3, 2026, marking a major regulatory milestone.

• Orviglance targets a global addressable market of $800 million annually, with the U.S. representing nearly half and over 100,000 annual procedures.

• Commercialization strategy focuses on partnering, with ongoing discussions and strong interest from potential partners.

• Oncoral, an oral irinotecan formulation, is advancing toward Phase 2 trials in gastric cancer, with a clinical collaboration established and a target market of $3 billion.

• Management changes, including the appointment of a new CFO and the departure of the Deputy CEO, as well as share conversions and incentive program vesting, were implemented to support future growth.

Financial highlights

• Q4 2025 operating loss was SEK 16 million, an improvement from previous quarters due to lower R&D costs after NDA submission.

• Liquid assets at year-end 2025 were SEK 49.9–50 million, with an additional SEK 30 million raised via a directed share issue in September.

• Cash runway extends into Q4 2026, beyond the expected FDA approval date for Orviglance.

• R&D costs accounted for 73% of operating costs in Q4 2025 and 76% for the full year.

• No net sales were reported; other operating income was minimal and related to exchange rate gains.

Outlook and guidance

• Anticipates FDA approval of Orviglance in July 2026 and subsequent commercialization through partnerships.

• Launch readiness and global partner-driven commercialization are prioritized.

• Oncoral Phase 2 in gastric cancer is progressing, with potential for expansion into other solid tumors.

• No specific revenue or cost guidance provided, but partnering is expected to impact future capital and cost structure.

• Optimistic about achieving key milestones and a strong 2026.